The safety of use of nonsteroidal anti-inflammatory drugs and paracetamol (acetaminophen) in pediatric hematology/oncology
Pediatric Hematology/Oncology and Immunopathology · 14.04.2026 · 25 (1) · 197-202
DOI: 10.24287/j.1048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 14.04.2026. Verfasst von M. A. Rybakova und 4 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aim: to analyze current data on the safety of nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol in children with oncological and hematological diseases considering the specific risks of this patient population. Materials and methods. We conducted a systematic literature review in PubMed, Cochrane Library, Web of Science and eLIBRARY databases, from 2020 to 2025, using the following keywords: “pediatric oncology”, “pediatric hematology”, “nonsteroidal anti-inflammatory drugs”, “paracetamol”, “acetaminophen”, “safety”, “thrombocytopenia”, “febrile neutropenia”, “drug interactions”, “pain”.
Results
The main risks of using NSAIDs and paracetamol in pediatric hematology/oncology were identified: hemorrhagic complications in patients with thrombocytopenia (individuals with platelet count 50 × 10⁹/L have a 2.5–4.0-fold increased risk), drug interactions with chemotherapy agents (especially with methotrexate), paracetamol-induced hepatotoxicity (elevated levels of alanine aminotransferase/aspartate aminotransferase in 15–25% of patients), renal toxicity of NSAIDs (acute kidney injury in 8–12% of patients). Safe dosages were established and clinical monitoring guidelines were developed. Paracetamol remains the treatment of choice in thrombocytopenia because it does not cause platelet aggregation.
Conclusion
The use of NSAIDs and paracetamol in pediatric hematology/oncology requires an individualized approach that would take into account patient’s hemostatic parameters, hepatic and renal function, ongoing chemotherapy and potential drug interactions. There is a need for further studies of the long-term safety of these drugs in this cohort of patients and for the development of clear clinical guidelines for their use.
Zitieren
APA
Rybakova, M. A., Kryukov, I. A., Ivanashkin, A. Y., Khamin, I. G., & Myakova, N. V. (2026). The safety of use of nonsteroidal anti-inflammatory drugs and paracetamol (acetaminophen) in pediatric hematology/oncology. Pediatric Hematology/Oncology and Immunopathology, 25(1), 197-202. https://doi.org/10.24287/j.1048
Vancouver
Rybakova MA, Kryukov IA, Ivanashkin AY, Khamin IG, Myakova NV. The safety of use of nonsteroidal anti-inflammatory drugs and paracetamol (acetaminophen) in pediatric hematology/oncology. Pediatric Hematology/Oncology and Immunopathology. 2026;25(1):197-202. doi:10.24287/j.1048
BibTeX
@article{Rybakova2026,
author = {Rybakova, M. A. and Kryukov, I. A. and Ivanashkin, A. Y. and Khamin, I. G. and Myakova, N. V.},
title = {The safety of use of nonsteroidal anti-inflammatory drugs and paracetamol (acetaminophen) in pediatric hematology/oncology},
journal = {Pediatric Hematology/Oncology and Immunopathology},
year = {2026},
volume = {25},
number = {1},
pages = {197--202},
doi = {10.24287/j.1048}
}
EUVIMED